Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 2/20 | 0.57 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.57 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.50 |
| ▸ | HASPIN | Q8TF76 | 10/20 | 0.48 |
| ▸ | PIM1 | P11309 | 3/20 | 0.48 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.48 |
| ▸ | CDK9 | P50750 | 3/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MELK | Q14680 | 1/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036768 | 1.00 | CLK1 (0.57) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156497 | 0.97 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156539 | 0.97 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156496 | 0.97 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156508 | 0.97 | CLK1 (0.55) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL445029 | 0.92 | CLK1 (0.52) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL13156540 | 0.89 | CLK1 (0.50) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| SCHEMBL1512981 | 0.89 | CLK1 (0.50) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| Methane SCHEMBL29190811 | 0.89 | CLK1 (0.50) | CLK1CSNK1DCSNK1EDYRK1APRKCZ | |
| Charcoal, Activated SCHEMBL30641848 | 0.89 | CLK1 (0.50) | CLK1CSNK1DCSNK1EDYRK1APRKCZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9207234-B2 | Thermally stable SERS taggants | SICPA HOLDING SA (CH) | 2015-12-08 | — | — | US | claimed |
| EP-2433121-A1 | THERMALLY STABLE SERS TAGGANTS | Cabot Security Materials Inc. (US) | 2012-03-28 | — | — | EP | claimed |
| US-20120062886-A1 | Thermally Stable SERS Taggants | CABOT SECURITY MATERIALS INC. (US) | 2012-03-15 | — | — | US | claimed |
| WO-2010135351-A1 | THERMALLY STABLE SERS TAGGANTS | OXONICA MATERIALS INC. (US) | 2010-11-25 | — | — | WO | claimed |
| US-20020160972-A1 | Compositions and methods for modulating RNA | ISIS PHARMACEUTICALS, INC. | 2002-10-31 | — | — | US | claimed |
| US-6358931-B1 | OLIGONUCLETIDE CONJUGATED TO IMIDAZOLE; INTERCALATION AND COORDINATION COMPOUNDS; MEDICAL DIAGNOSIS, GENE THERAPY; ANTISENSE AGENTS | ISIS PHARMACEUTICALS, INC. | 2002-03-19 | — | — | US | claimed |
| US-5994365-A | BACTERICIDES; FUNGICIDES; ANTITUMOR AGENT | DIAZANS LIMITED (CA) | 1999-11-30 | — | — | US | claimed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | claimed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | claimed |
| US-20250073225-A1 | BIFUNCTIONAL COMPOSITIONS FOR THE TREATMENT OF CANCER | ARMACEUTICA INC (US) | 2025-03-06 | — | — | US | disclosed |
| US-12201626-B2 | Bifunctional compositions for the treatment of cancer | Armaceutica, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| EP-3793544-B1 | BIFUNCTIONAL COMPOSITIONS FOR THE TREATMENT OF CANCER | ARMACEUTICA INC (US) | 2023-09-20 | — | — | EP | disclosed |
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | IONIS PHARMACEUTICALS, INC. (US) | 2022-09-15 | — | — | US | disclosed |
| US-20210361643-A1 | BIFUNCTIONAL COMPOSITIONS FOR THE TREATMENT OF CANCER | ARMACEUTICA INC (US) | 2021-11-25 | — | — | US | disclosed |
| US-6060592-A | Pyrimidine nucleoside compounds and oligonucleoside compounds containing same | ISIS PHARMACEUTICALS, INC. (US) | 2000-05-09 | — | — | US | disclosed |
| US-5994365-A | BACTERICIDES; FUNGICIDES; ANTITUMOR AGENT | DIAZANS LIMITED (CA) | 1999-11-30 | — | — | US | disclosed |
| US-5514786-A | Compositions for inhibiting RNA activity | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-07 | — | — | US | disclosed |
| WO-1995024185-A1 | NOVEL PYRIMIDINE NUCLEOSIDES | ISIS PHARMACEUTICALS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0656790-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1995-06-14 | — | — | EP | disclosed |
| WO-1993017717-A1 | COMPOSITIONS AND METHODS FOR MODULATING RNA | ISIS PHARMACEUTICALS, INC. (US) | 1993-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160972-A1 | Compositions and methods for modulating RNA | RNGTT, NSUN3, NSUN2 | CLK1 4180/4885CSNK1D 2593/4885CSNK1E 1856/4885 |
| US-20220288100-A1 | 2'-METHOXY SUBSTITUTED OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN GENE MODULATIONS | NSUN2, SNRPE, RBM3 | CLK1 3485/4885CSNK1D 3997/4885CSNK1E 2989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.